Unlike the synthetic COX-2 inhibitors, EPA and DHA are associated with a reduced risk of cardiovascular disease and sudden cardiac death (Holub and Holub, 2004; Harrison and Abhyankar, 2005). The gene discussed is PTGS2; the disease is cardiovascular disorder.